Predictive Chemistry: Quantitative Structure-Activity Relationship (QSAR) Quiz

Flexible molecules can adopt many shapes, only one of which fits the receptor. By locking the molecule into its "bioactive conformation" using rings or double bonds, chemists reduce the energy lost when the molecule stops rotating to bind. This lower entropic cost directly translates to a higher binding affinity and increased potency.

This is false. The Pharmacophore is the essential part. The Auxophore refers to the rest of the molecule—the "extra" parts that do not bind the target directly but can be modified to improve properties like solubility, stability, or to add features that enhance selectivity.

Even if the core pharmacophore is present, potency can often be boosted by adding small groups that tap into nearby, unoccupied pockets. Filling these "extra" spaces with appropriate groups (like a methyl for a hydrophobic hole) provides additional Van der Waals interactions, strengthening the overall drug-receptor complex.

Selectivity is about hitting one target and missing others. This can be achieved by designing the drug to interact with an amino acid present only in the target protein, or by using "isoform-specific" pockets. Irreversible inhibitors, however, often increase the risk of toxicity if they bind to the wrong protein permanently.

By adding branches to an alkyl chain, chemists can determine how much physical space is available in a receptor pocket. If a branched chain increases potency, it suggests a large pocket; if it decreases potency, it indicates a tight, constrained space. This helps map the "topography" of the binding site.

This is true. If a receptor has an additional binding region (like a secondary ionic site) just outside the main active site, chemists can "extend" the lead molecule by adding a tether and a matching functional group. This creates a multi-point attachment that significantly increases both affinity and selectivity.

Certain chemical shapes, like benzodiazepines or indoles, appear frequently in successful drugs because they are "pre-organized" to interact well with common protein features. Using these scaffolds as a starting point allows chemists to rapidly create libraries of compounds that have a higher statistical chance of being biologically active.

Natural products are often overly complex and contain "extra" atoms not needed for activity. Simplifying them makes them easier and cheaper to build in a lab. However, removing too much structure can sometimes make a molecule less selective, as a smaller, simpler molecule might fit into the active sites of many different proteins.

Sometimes, adding a single methyl group in exactly the right spot can increase potency by 100-fold or more. This occurs when the methyl group perfectly fills a hydrophobic pocket or forces the rest of the molecule into its bioactive conformation through steric effects, effectively "supercharging" the drug's fit.

FBLD starts with very small, weak-binding molecules (fragments). If two fragments are found that bind in nearby spots, they are chemically linked. Because the binding energies of the two fragments combine multiplicatively, the resulting linked molecule is often thousands of times more potent than the individual pieces.

This is correct. If a ring system is slightly too small or too large, the functional groups attached to it won't align perfectly with the receptor's partners. Changing a 6-membered ring to a 5- or 7-membered ring shifts the "vectors" of the substituents, allowing the chemist to find the optimal geometry for maximum binding energy.

Fluorine is a unique tool. It is small (minimal steric change) but highly electronegative. Moving a fluorine atom around a ring helps identify where the receptor prefers electron-dense or electron-poor regions. It also blocks metabolism and can subtly increase the drug's ability to cross membranes.

Most drugs are flexible and can "wiggle" into many shapes. However, only one specific shape allows for the perfect alignment of all binding forces with the receptor. A major goal of medicinal chemistry is to ensure the drug spends as much time as possible in this bioactive shape, rather than in "inactive" conformations.

Oxygen atoms are smaller than sulfur atoms. While they are in the same group of the periodic table, the shift from a 3rd-period element (S) to a 2nd-period element (O) reduces the bond lengths and the overall volume. This can be used to "shrink" a molecule that is slightly too bulky for its target pocket.

This is false. A drug must be more than just potent; it must be safe (selective), soluble, stable, and able to reach its target. A "super-potent" molecule that is toxic to the liver or cannot be absorbed by the gut will fail in clinical trials. Successful medicinal chemistry requires a balance of potency, selectivity, and "druglike" properties (ADME).